Greater investment in AI and data security are among the keys.
The COVID-19 pandemic brought on an era in which nearly every activity of our lives went digital. And while many yearn for a return to pre-pandemic days in the healthcare business, the “new normal” is here to stay with even more progression from digital health (the gathering of information) to data-driven healthcare (actionable decisions based on the data). When this happens, organizations will need to demonstrate how this will improve healthcare services in quality, access and efficiency:
The digital transformation of healthcare will be key to achieving these objectives. Below are steps the healthcare industry needs to take to move from simply digital health to data-driven healthcare.
1. Identify and invest. Healthcare organizations need to invest further in AI and other related advanced technologies.Clinical workflows will become more agile by virtue of AI and advanced analytics that automate decision-making processes. The emergence of these technologies requires a transformation from digital health to data-driven healthcare given the fundamental role of data in automated decision making.
2. Improve big data analysis, data quality and availability. Technological devices generate huge amounts of data that can be analyzed to provide real-time clinical or medical care. To extract meaningful value, the data must feature 4 factors to provide important benefits including more accurate staffing; facilitation of chronic care; and a lower rate of medication errors.
3. Embrace technology trends. When done systematically and on a large scale, relatively simple technology solutions will reduce the cost of improving health outcomes. The next generation of innovations including the use of AI and precision medicine, in combining big data analytics and machine learning (ML) algorithms, will enable us to leverage this data better and give rise to new use cases and ways of working.
4. Data security. For an adequate level of data protection, organizations need to follow a blueprint which should include setting up a dedicated corporate figure/committee to (1) monitor and assess regulatory compliance for data processing, (2) define and update data management policies, (3) provide training for those dealing with health data, and (4) implement “secure by design” information systems.
5. Skills development. Insufficient data analytics talent has been a perennial pain point for the healthcare industry. Significant investment in trained teams of data analysts, data managers, and data stewards will be needed to manage the gathering and analysis of data, while developers are needed in software development.
Rebecka Axelsson Wadman
Even with all of these benefits to patient care, healthcare leaders will need to be prepared for some levels of resistance. The key is to communicate effectively with a seriousness of purpose why these advances matter and how their use will directly maintain and improve patient care.
Rebecka Axelsson Wadman is a principal at Arthur D. Little with deep industry expertise in healthcare and life sciences.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Leadership Team at The Cigna Group Revamps in Efforts to Drive Growth, Enhance Customer Focus
March 13th 2025David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More